Severe COVID-19 disease is associated with genetic factors affecting plasma ACE2 receptor and CRP concentrations.

Publication date: Feb 08, 2025

A hyperinflammatory state with highly elevated concentrations of inflammatory biomarkers such as C-reactive protein (CRP) is a characteristic feature of severe coronavirus disease 2019 (COVID-19). To examine a potential role of common genetic factors that may influence COVID-19 outcomes, we investigated whether individuals with a polygenic predisposition for a pro-inflammatory response (in the form of Polygenic Scores) are more likely to develop severe COVID-19. The innovative approach of polygenic scores to investigate genetic factors in COVID-19 severity should provide a comprehensive approach beyond single-gene studies. In our cohort of 156 patients of European ancestry, two overlapping Polygenic Scores (PGS) predicting a genetic predisposition to basal CRP concentrations were significantly different between non-severe and severe COVID-19 cases and were associated with less severe COVID-19 outcomes. Furthermore, specific single nucleotide polymorphisms (SNPs) that contribute to either of the two Polygenic Scores predicting basal CRP levels are associated with different traits that represent risk factors for COVID-19 disease initiation (ACE2 receptor, viral replication) and progression (CRP). We suggest that genetically determined enforced CRP formation may contribute to strengthening of innate immune responses and better initial pathogen control thereby reducing the risk of subsequent hyperinflammation and adverse course of COVID-19.

Open Access PDF

Concepts Keywords
Biomarkers ACE2 protein, human
Common Adult
Coronavirus Aged
Covid Angiotensin-Converting Enzyme 2
Hyperinflammatory Angiotensin-Converting Enzyme 2
Biomarkers
Biomarkers
C-Reactive Protein
C-Reactive Protein
COVID-19
Female
Humans
Male
Middle Aged
Multifactorial Inheritance
Polymorphism, Single Nucleotide
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease IDO role
pathway KEGG Viral replication
drug DRUGBANK Tropicamide
disease IDO pathogen
disease MESH Long Covid
disease IDO host
disease IDO innate immune response
disease MESH defects
pathway REACTOME Interferon Signaling
disease MESH cytokine storm
disease MESH acute respiratory distress syndrome
disease MESH respiratory failure
disease MESH death
disease MESH infection
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease IDO susceptibility
drug DRUGBANK Pidolic Acid
disease MESH Malignancy
disease IDO immunosuppression
disease MESH Coronary artery disease
disease MESH Heart failure
disease MESH hypertension
disease MESH COPD
disease MESH Asthma
pathway KEGG Asthma
disease MESH fibrosis
disease MESH Chronic kidney diseases
disease MESH Diabetes mellitus
disease MESH Venous thromboembolism
disease IDO blood
drug DRUGBANK Nesiritide
drug DRUGBANK Cholesterol
disease MESH dengue
disease MESH viral load
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
pathway REACTOME Infectious disease
disease IDO infectious disease
disease MESH critical illness
disease MESH chronic conditions
disease MESH obesity
disease MESH cardiovascular diseases
disease MESH pneumonia
disease MESH viral infection
disease MESH atrial fibrillation
disease IDO bacteria
disease MESH superinfection
disease MESH inflammation
drug DRUGBANK Angiotensin II
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO intervention
disease MESH Hepatitis B
pathway KEGG Hepatitis B
drug DRUGBANK Oxygen
drug DRUGBANK Edetic Acid
disease IDO assay
disease IDO quality
drug DRUGBANK Guanosine
pathway REACTOME Innate Immune System
disease IDO cell
disease MESH Hypercoagulability
disease MESH Shock
disease MESH syndromes
disease MESH Genetic risk scores
disease MESH abdominal aortic aneurysm
disease MESH gestational diabetes mellitus
disease MESH metabolic syndrome
disease MESH Anemia
disease MESH atrophy
disease MESH Streptococcus pneumoniae infection
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)